tiprankstipranks
AbbVie (ABBV)
NYSE:ABBV
US Market
ABBV
AbbVie
RESEARCH TOOLSreports

AbbVie (ABBV) Stock Forecast & Price Target

23,706 Followers
See the Price Targets and Ratings of:

ABBV Analyst Ratings

Moderate Buy
23Ratings
Moderate Buy
15 Buy
8 Hold
0 Sell
Based on 23 analysts giving stock ratings to
AbbVie
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

ABBV Stock 12 Month Forecast

Average Price Target

$253.47
▲(21.37% Upside)
Based on 23 Wall Street analysts offering 12 month price targets for AbbVie in the last 3 months. The average price target is $253.47 with a high forecast of $299.00 and a low forecast of $223.00. The average price target represents a 21.37% change from the last price of $208.84.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"181":"$181","300":"$300","210.75":"$210.8","240.5":"$240.5","270.25":"$270.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":299,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$299.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":253.47368421052633,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$253.47</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":223,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$223.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[181,210.75,240.5,270.25,300],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2025","6":"Oct<br/>2025","9":"Jan<br/>2026","12":"Apr<br/>2026","25":"Apr<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,214.98,221.44307692307692,227.90615384615384,234.36923076923077,240.8323076923077,247.29538461538462,253.75846153846152,260.22153846153844,266.68461538461537,273.1476923076923,279.6107692307692,286.07384615384615,292.5369230769231,{"y":299,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,214.98,217.94105263157894,220.9021052631579,223.86315789473684,226.8242105263158,229.78526315789475,232.74631578947367,235.70736842105265,238.66842105263157,241.62947368421052,244.59052631578948,247.55157894736843,250.51263157894738,{"y":253.47368421052633,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,214.98,215.59692307692308,216.21384615384613,216.83076923076922,217.4476923076923,218.06461538461537,218.68153846153845,219.29846153846154,219.91538461538462,220.53230769230768,221.14923076923077,221.76615384615386,222.3830769230769,{"y":223,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":199.575,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":188.793,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":182.592,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":185.522,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":192.275,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":207.226,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":240.694,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":216.299,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":223.313,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":226.666,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":225.64,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":234.26,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":214.98,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$299.00Average Price Target$253.47Lowest Price Target$223.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
BMO Capital Analyst forecast on ABBV
Evan Seigerman
BMO Capital
BMO Capital
$258
Buy
23.54%
Upside
Reiterated
04/01/26
AbbVie: Resilient Core, Growing Aesthetics, and Strategic Acquisitions Underpin Buy Rating
Erste Group Analyst forecast on ABBV
Hans Engel
Erste Group
Erste Group
―
Hold
―
Reiterated
04/01/26
Analysts Offer Insights on Healthcare Companies: AbbVie (NYSE: ABBV) and Viridian Therapeutics (NASDAQ: VRDN)
Bernstein Analyst forecast on ABBV
Courtney Breen
Bernstein
Bernstein
$225
Hold
7.74%
Upside
Reiterated
03/30/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: AbbVie (NYSE: ABBV), Molina Healthcare (NYSE: MOH) and Ocular Therapeutix (NASDAQ: OCUL)
Piper Sandler Analyst forecast on ABBV
David Amsellem
Piper Sandler
Piper Sandler
$299
Buy
43.17%
Upside
Reiterated
03/26/26
Piper Sandler Keeps Their Buy Rating on AbbVie (ABBV)
Wells Fargo Analyst forecast on ABBV
Mohit Bansal
Wells Fargo
Wells Fargo
$260
Buy
24.50%
Upside
Assigned
03/12/26
Analysts Are Bullish on Top Healthcare Stocks: AbbVie (ABBV), Relay Therapeutics (RLAY)
Berenberg Bank Analyst forecast on ABBV
Luisa Hector
Berenberg Bank
Berenberg Bank
$275
Buy
31.68%
Upside
Reiterated
03/12/26
AbbVie (ABBV) Receives a Buy from Berenberg Bank
Citi Analyst forecast on ABBV
Geoff Meacham
Citi
Citi
$230
Hold
10.13%
Upside
Reiterated
03/10/26
Neutral Hold on AbbVie as Early Cardiometabolic Pipeline Shows Promise but Trails Leading Competitors
Scotiabank Analyst forecast on ABBV
Louise Chen
Scotiabank
Scotiabank
$280
Buy
34.07%
Upside
Reiterated
03/10/26
Scotiabank Reaffirms Their Buy Rating on AbbVie (ABBV)
William Blair Analyst forecast on ABBV
Matt Phipps
William Blair
William Blair
―
Buy
―
Reiterated
03/09/26
Analysts Offer Insights on Healthcare Companies: AbbVie (NYSE: ABBV) and Delcath Systems (NASDAQ: DCTH)
J.P. Morgan Analyst forecast on ABBV
Chris Schott
J.P. Morgan
J.P. Morgan
$260
Buy
24.50%
Upside
Reiterated
03/05/26
J.P. Morgan Sticks to Its Buy Rating for AbbVie (ABBV)
Morgan Stanley Analyst forecast on ABBV
Terence Flynn
Morgan Stanley
Morgan Stanley
$269→$270
Buy
29.29%
Upside
Reiterated
03/02/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
DBS Analyst forecast on ABBV
Nico Chen
DBS
DBS
$230
Hold
10.13%
Upside
Reiterated
02/25/26
DBS Sticks to Their Hold Rating for AbbVie (ABBV)
RBC Capital Analyst forecast on ABBV
Trung Huynh
RBC Capital
RBC Capital
$260
Buy
24.50%
Upside
Initiated
02/24/26
AbbVie initiated with an Outperform at RBC CapitalAbbVie initiated with an Outperform at RBC Capital
Barclays Analyst forecast on ABBV
Emily Field
Barclays
Barclays
$275
Buy
31.68%
Upside
Initiated
02/19/26
AbbVie initiated with an Overweight at BarclaysAbbVie initiated with an Overweight at Barclays
Guggenheim Analyst forecast on ABBV
Unknown Analyst
Guggenheim
Not Ranked
Guggenheim
$242
Buy
15.88%
Upside
Reiterated
02/05/26
AbbVie (ABBV) Receives a Buy from Guggenheim
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
BMO Capital Analyst forecast on ABBV
Evan Seigerman
BMO Capital
BMO Capital
$258
Buy
23.54%
Upside
Reiterated
04/01/26
AbbVie: Resilient Core, Growing Aesthetics, and Strategic Acquisitions Underpin Buy Rating
Erste Group Analyst forecast on ABBV
Hans Engel
Erste Group
Erste Group
―
Hold
―
Reiterated
04/01/26
Analysts Offer Insights on Healthcare Companies: AbbVie (NYSE: ABBV) and Viridian Therapeutics (NASDAQ: VRDN)
Bernstein Analyst forecast on ABBV
Courtney Breen
Bernstein
Bernstein
$225
Hold
7.74%
Upside
Reiterated
03/30/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: AbbVie (NYSE: ABBV), Molina Healthcare (NYSE: MOH) and Ocular Therapeutix (NASDAQ: OCUL)
Piper Sandler Analyst forecast on ABBV
David Amsellem
Piper Sandler
Piper Sandler
$299
Buy
43.17%
Upside
Reiterated
03/26/26
Piper Sandler Keeps Their Buy Rating on AbbVie (ABBV)
Wells Fargo Analyst forecast on ABBV
Mohit Bansal
Wells Fargo
Wells Fargo
$260
Buy
24.50%
Upside
Assigned
03/12/26
Analysts Are Bullish on Top Healthcare Stocks: AbbVie (ABBV), Relay Therapeutics (RLAY)
Berenberg Bank Analyst forecast on ABBV
Luisa Hector
Berenberg Bank
Berenberg Bank
$275
Buy
31.68%
Upside
Reiterated
03/12/26
AbbVie (ABBV) Receives a Buy from Berenberg Bank
Citi Analyst forecast on ABBV
Geoff Meacham
Citi
Citi
$230
Hold
10.13%
Upside
Reiterated
03/10/26
Neutral Hold on AbbVie as Early Cardiometabolic Pipeline Shows Promise but Trails Leading Competitors
Scotiabank Analyst forecast on ABBV
Louise Chen
Scotiabank
Scotiabank
$280
Buy
34.07%
Upside
Reiterated
03/10/26
Scotiabank Reaffirms Their Buy Rating on AbbVie (ABBV)
William Blair Analyst forecast on ABBV
Matt Phipps
William Blair
William Blair
―
Buy
―
Reiterated
03/09/26
Analysts Offer Insights on Healthcare Companies: AbbVie (NYSE: ABBV) and Delcath Systems (NASDAQ: DCTH)
J.P. Morgan Analyst forecast on ABBV
Chris Schott
J.P. Morgan
J.P. Morgan
$260
Buy
24.50%
Upside
Reiterated
03/05/26
J.P. Morgan Sticks to Its Buy Rating for AbbVie (ABBV)
Morgan Stanley Analyst forecast on ABBV
Terence Flynn
Morgan Stanley
Morgan Stanley
$269→$270
Buy
29.29%
Upside
Reiterated
03/02/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
DBS Analyst forecast on ABBV
Nico Chen
DBS
DBS
$230
Hold
10.13%
Upside
Reiterated
02/25/26
DBS Sticks to Their Hold Rating for AbbVie (ABBV)
RBC Capital Analyst forecast on ABBV
Trung Huynh
RBC Capital
RBC Capital
$260
Buy
24.50%
Upside
Initiated
02/24/26
AbbVie initiated with an Outperform at RBC CapitalAbbVie initiated with an Outperform at RBC Capital
Barclays Analyst forecast on ABBV
Emily Field
Barclays
Barclays
$275
Buy
31.68%
Upside
Initiated
02/19/26
AbbVie initiated with an Overweight at BarclaysAbbVie initiated with an Overweight at Barclays
Guggenheim Analyst forecast on ABBV
Unknown Analyst
Guggenheim
Not Ranked
Guggenheim
$242
Buy
15.88%
Upside
Reiterated
02/05/26
AbbVie (ABBV) Receives a Buy from Guggenheim
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
xxx
xxx
xxx
xxx
xxx
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering AbbVie

3 Months
xxx
Success Rate
17/23 ratings generated profit
74%
Average Return
+6.44%
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 3 Months would result in 73.91% of your transactions generating a profit, with an average return of +6.44% per trade.
1 Year
Evan SeigermanBMO Capital
Success Rate
19/20 ratings generated profit
95%
Average Return
+17.14%
Copying Evan Seigerman's trades and holding each position for 1 Year would result in 95.00% of your transactions generating a profit, with an average return of +17.14% per trade.
2 Years
xxx
Success Rate
28/29 ratings generated profit
97%
Average Return
+31.94%
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 2 Years would result in 96.55% of your transactions generating a profit, with an average return of +31.94% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ABBV Analyst Recommendation Trends

Rating
Dec 25
Jan 26
Feb 26
Mar 26
Apr 26
Strong Buy
0
0
0
0
0
Buy
32
28
28
30
21
Hold
16
15
14
14
7
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
48
43
42
44
28
In the current month, ABBV has received 21 Buy Ratings, 7 Hold Ratings, and 0 Sell Ratings. ABBV average Analyst price target in the past 3 months is 253.47.
Each month's total comprises the sum of three months' worth of ratings.

ABBV Financial Forecast

ABBV Earnings Forecast

Next quarter’s earnings estimate for ABBV is $3.02 with a range of $2.97 to $3.17. The previous quarter’s EPS was $2.71. ABBV beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year ABBV has Performed in-line its overall industry.
Next quarter’s earnings estimate for ABBV is $3.02 with a range of $2.97 to $3.17. The previous quarter’s EPS was $2.71. ABBV beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year ABBV has Performed in-line its overall industry.

ABBV Sales Forecast

Next quarter’s sales forecast for ABBV is $14.72B with a range of $14.56B to $14.85B. The previous quarter’s sales results were $16.62B. ABBV beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year ABBV has Performed in-line its overall industry.
Next quarter’s sales forecast for ABBV is $14.72B with a range of $14.56B to $14.85B. The previous quarter’s sales results were $16.62B. ABBV beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year ABBV has Performed in-line its overall industry.

ABBV Stock Forecast FAQ

What is ABBV’s average 12-month price target, according to analysts?
Based on analyst ratings, AbbVie’s 12-month average price target is 253.47.
    What is ABBV’s upside potential, based on the analysts’ average price target?
    AbbVie has 21.37% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is ABBV a Buy, Sell or Hold?
          AbbVie has a consensus rating of Moderate Buy which is based on 15 buy ratings, 8 hold ratings and 0 sell ratings.
            What is AbbVie’s price target?
            The average price target for AbbVie is 253.47. This is based on 23 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $299.00 ,the lowest forecast is $223.00. The average price target represents 21.37% Increase from the current price of $208.84.
              What do analysts say about AbbVie?
              AbbVie’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 23 Wall Streets Analysts.
                How can I buy shares of ABBV?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.